Unnamed: 0,title,date,stock,sentiment
296933.0,Stocks That Hit 52-Week Highs On Wednesday,2020-06-03 10:45:00-04:00,CRL,neutral
296934.0,Stocks That Hit 52-Week Highs On Tuesday,2020-06-02 10:33:00-04:00,CRL,neutral
296935.0,"Benzinga's Top Upgrades, Downgrades For May 13, 2020",2020-05-13 09:58:00-04:00,CRL,positive
296936.0,"UBS Upgrades Charles River to Buy, Raises Price Target of $200",2020-05-13 07:44:00-04:00,CRL,neutral
296937.0,"Deutsche Bank Maintains Buy on Charles River, Lowers Price Target to $174",2020-05-12 09:20:00-04:00,CRL,negative
296938.0,"JP Morgan Maintains Overweight on Charles River, Raises Price Target to $180",2020-05-08 12:03:00-04:00,CRL,neutral
296939.0,"SunTrust Robinson Humphrey Maintains Buy on Charles River, Raises Price Target to $194",2020-05-08 10:54:00-04:00,CRL,neutral
296940.0,"Credit Suisse Maintains Neutral on Charles River, Lowers Price Target to $159",2020-05-08 10:42:00-04:00,CRL,positive
296941.0,"Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $175",2020-05-08 08:14:00-04:00,CRL,negative
296942.0,"Citigroup Maintains Buy on Charles River, Raises Price Target to $190",2020-05-08 07:17:00-04:00,CRL,neutral
296943.0,Charles River Laboratories Sees FY20 Adj. EPS $6.75-$7.10 vs $6.44,2020-05-07 07:17:00-04:00,CRL,neutral
296944.0,"Charles River Q1 Adj. EPS $1.840 Beats $1.470 Estimate, Sales $707.100M Beat $691.090M Estimate",2020-05-07 07:16:00-04:00,CRL,neutral
296945.0,"Earnings Scheduled For May 7, 2020",2020-05-07 05:02:00-04:00,CRL,neutral
296946.0,"Benzinga's Top Upgrades, Downgrades For April 21, 2020",2020-04-21 09:35:00-04:00,CRL,positive
296947.0,Jefferies Downgrades Charles River to Hold,2020-04-21 06:54:00-04:00,CRL,neutral
296948.0,"Citigroup Maintains Buy on Charles River, Lowers Price Target to $165",2020-04-09 08:14:00-04:00,CRL,negative
296949.0,"SunTrust Robinson Humphrey Maintains Buy on Charles River, Raises Price Target to $130",2020-04-06 12:32:00-04:00,CRL,neutral
296950.0,"Wells Fargo Maintains Overweight on Charles River, Lowers Price Target to $145",2020-03-30 10:44:00-04:00,CRL,negative
296951.0,Charles River Laboratories And Deciphex Form Partnership To 'Enhance Drug Discovery & Development With Digital Pathology',2020-03-30 08:37:00-04:00,CRL,neutral
296952.0,Morgan Stanley Upgrades Charles River to Overweight,2020-03-27 05:09:00-04:00,CRL,negative
296953.0,"Barclays Maintains Equal-Weight on Charles River, Lowers Price Target to $154",2020-03-26 10:42:00-04:00,CRL,negative
296954.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,CRL,negative
296955.0,"CORRECTION: Jefferies Maintains Buy On Charles River Labs, Lowers Target To $139; Initial Headline Had Incorrect Ticker",2020-03-23 09:30:00-04:00,CRL,negative
296956.0,"Jefferies Maintains Buy on Charles River Labs, Lowers Price Target to $139",2020-03-23 09:21:00-04:00,CRL,negative
296957.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,CRL,negative
296958.0,"SunTrust Robinson Humphrey Maintains Buy on Charles River, Lowers Price Target to $124",2020-03-17 12:07:00-04:00,CRL,negative
296959.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,CRL,negative
296960.0,"Benzinga's Top Upgrades, Downgrades For March 2, 2020",2020-03-02 09:40:00-05:00,CRL,positive
296961.0,"Deutsche Bank Initiates Coverage On Charles River with Buy Rating, Announces $190 Price Target",2020-03-02 07:27:00-05:00,CRL,neutral
296962.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-19 10:32:00-05:00,CRL,neutral
296963.0,"Wolfe Research Upgrades Charles River to Outperform, Raises Price Target to $203",2020-02-18 11:19:00-05:00,CRL,neutral
296964.0,"Baird Maintains Outperform on Charles River, Raises Price Target to $185",2020-02-12 11:04:00-05:00,CRL,neutral
296965.0,"Morgan Stanley Maintains Equal-Weight on Charles River, Raises Price Target to $176",2020-02-12 09:21:00-05:00,CRL,neutral
296966.0,94 Biggest Movers From Yesterday,2020-02-12 05:13:00-05:00,CRL,neutral
296967.0,"CFRA Maintains Strong Buy on Charles River, Raises Price Target to $180",2020-02-11 13:59:00-05:00,CRL,positive
296968.0,71 Stocks Moving In Tuesday's Mid-Day Session,2020-02-11 12:21:00-05:00,CRL,neutral
296969.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,CRL,neutral
296970.0,Charles River Laboratories Sees FY20 Adj. EPS $7.45-$7.60 vs $7.41 Est.,2020-02-11 07:03:00-05:00,CRL,neutral
296971.0,"Charles River Q4 EPS $2.01 Beats $1.83 Estimate, Sales $691.1M Beat $685.31M Estimate",2020-02-11 07:03:00-05:00,CRL,neutral
296972.0,"Earnings Scheduled For February 11, 2020",2020-02-11 04:27:00-05:00,CRL,neutral
296973.0,Charles River Labs Reports Formation Of Strategic Alliance With Fios Genomics,2020-01-16 08:14:00-05:00,CRL,neutral
296974.0,Kerrisdale Capital To Present Long Thesis On Charles River Laboratories At 4:00 p.m.  ET (Link),2020-01-10 15:08:00-05:00,CRL,neutral
296975.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,CRL,neutral
296976.0,"Benzinga's Top Upgrades, Downgrades For January 10, 2020",2020-01-10 12:16:00-05:00,CRL,positive
296977.0,"Goldman Sachs Upgrades Charles River to Buy, Raises Price Target to $170",2020-01-10 08:47:00-05:00,CRL,neutral
296978.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,CRL,neutral
296979.0,"Benzinga's Top Upgrades, Downgrades For January 8, 2020",2020-01-08 10:56:00-05:00,CRL,positive
296980.0,"Wells Fargo Initiates Coverage On Charles River with Overweight Rating, Announces $180 Price Target",2020-01-08 08:57:00-05:00,CRL,negative
296981.0,"Citigroup Initiates Coverage On Charles River with Buy Rating, Announces $185 Price Target",2020-01-07 07:12:00-05:00,CRL,neutral
296982.0,Stocks That Hit 52-Week Highs On Friday,2019-12-27 11:27:00-05:00,CRL,neutral
296983.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,CRL,neutral
296984.0,"Baird Maintains Outperform on Charles River, Raises Price Target to $165",2019-12-17 08:21:00-05:00,CRL,neutral
296985.0,Stocks That Hit 52-Week Highs On Monday,2019-12-16 10:16:00-05:00,CRL,neutral
296986.0,Charles River Labs to Acquire HemaCare for $380M Cash,2019-12-16 07:28:00-05:00,CRL,neutral
296987.0,"KeyBanc Maintains Overweight on Charles River, Raises Price Target to $162",2019-12-09 05:49:00-05:00,CRL,negative
296988.0,"UBS Maintains Neutral on Charles River, Lowers Price Target to $145",2019-11-07 07:38:00-05:00,CRL,negative
296989.0,Charles River Narrows FY19 EPS Guidance From $6.45-$6.60 To $6.50-$6.60 Vs. $6.52 Est.,2019-11-06 07:50:00-05:00,CRL,neutral
296990.0,"Charles River Q3 EPS $1.69 Beats $1.63 Estimate, Sales $667.951M Miss $672.74M Estimate",2019-11-06 07:48:00-05:00,CRL,negative
296991.0,"Benzinga's Top Upgrades, Downgrades For October 18, 2019",2019-10-18 09:53:00-04:00,CRL,positive
296992.0,Bank of America Downgrades Charles River to Neutral,2019-10-18 07:04:00-04:00,CRL,neutral
296993.0,"SunTrust Robinson Humphrey Maintains Buy on Charles River, Raises Price Target to $162",2019-09-16 10:27:00-04:00,CRL,neutral
296994.0,"Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance.",2019-08-06 13:54:00-04:00,CRL,positive
296995.0,Charles River Laboratories Raises FY19 Adj. EPS Guidance From $6.40-$6.55 To $6.45-$6.60 vs $6.47 Est.,2019-07-31 07:22:00-04:00,CRL,neutral
296996.0,"Charles River Q2 Ad. EPS $1.63 Beats $1.55 Estimate, Sales $657.6M Miss $662.51M Estimate",2019-07-31 07:21:00-04:00,CRL,negative
296997.0,"Earnings Scheduled For July 31, 2019",2019-07-31 04:03:00-04:00,CRL,neutral
296998.0,Many US-traded stocks are trading higher as recent economic signals have raised the potential for a Federal Reserve rate cut.,2019-06-07 12:31:00-04:00,CRL,negative
296999.0,"Many stocks are trading lower amid continued uncertainty about the future of trade between the US and China, and concerns on U.S. sanctions on Iran and Venezuela.",2019-05-07 11:19:00-04:00,CRL,negative
297000.0,"Charles River Q1 EPS $1.4 Beats $1.38 Estimate, Sales $604.569M Beat $595.66M Estimate",2019-05-07 07:40:00-04:00,CRL,neutral
297001.0,"Earnings Scheduled For May 7, 2019",2019-05-07 05:03:00-04:00,CRL,neutral
297002.0,"KeyBanc Maintains Overweight on Charles River, Raises Price Target to $151",2019-03-11 11:06:00-04:00,CRL,negative
297003.0,58 Biggest Movers From Yesterday,2019-02-14 05:35:00-05:00,CRL,neutral
297004.0,42 Stocks Moving In Wednesday's Mid-Day Session,2019-02-13 12:25:00-05:00,CRL,neutral
297005.0,"Charles River Laboratories shares are trading higher after the company reported Q4 EPS of $1.49, beating the $1.40 estimate and Q4 sales of $601.5 million, beating the $590.75 million estimate; the company reported it sees FY19 sales growth of 10%-15%.",2019-02-13 11:33:00-05:00,CRL,negative
297006.0,Charles River Laboratories Signs Binding Offer To Acquire Citoxlab For ~$510M In Cash,2019-02-13 07:15:00-05:00,CRL,neutral
297007.0,"Charles River Sees FY19 Adj. EPS $6.25-$6.40 vs $6.35 Est., Sees Sales Growth 10%-15%",2019-02-13 07:09:00-05:00,CRL,positive
297008.0,"Charles River Q4 Adj. EPS $1.49 Beats $1.40 Estimate, Sales $601.5M Beat $590.75M Estimate",2019-02-13 07:06:00-05:00,CRL,neutral
297009.0,"Earnings Scheduled For February 13, 2019",2019-02-13 04:05:00-05:00,CRL,neutral
297010.0,Charles River Labs Reports Deal With Toxys For ToxTracker In North America,2019-01-30 08:08:00-05:00,CRL,neutral
297011.0,"Jim Cramer Shares His Thoughts On JPMorgan, PRA Health Sciences And Funko",2018-12-07 07:38:00-05:00,CRL,positive
297012.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,CRL,neutral
297013.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,CRL,neutral
297014.0,"Morgan Stanley Maintains Equal-Weight on Charles River, Raises Price Target to $136",2018-12-03 09:11:00-05:00,CRL,neutral
297015.0,"Raymond James Maintains Outperform on Charles River, Raises Price Target to $150",2018-11-08 12:13:00-05:00,CRL,neutral
297016.0,"Baird Maintains Outperform on Charles River, Raises Price Target to $148",2018-11-08 12:03:00-05:00,CRL,neutral
297017.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,CRL,neutral
297018.0,"RBC Capital Maintains Outperform on Charles River, Raises Price Target to $147",2018-11-08 09:45:00-05:00,CRL,neutral
297019.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,CRL,negative
297020.0,Charles River Cuts FY18 Adj. EPS Guidance From $5.85-$6 To $5.87-$5.97 vs $5.92 Estimate,2018-11-07 07:18:00-05:00,CRL,negative
297021.0,"Charles River Q3 EPS $1.53 Beats $1.38 Estimate, Sales $585.3M Beat $567.79M Estimate",2018-11-07 07:18:00-05:00,CRL,neutral
297022.0,"Earnings Scheduled For November 7, 2018",2018-11-07 03:51:00-05:00,CRL,neutral
297023.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,CRL,neutral
297024.0,"Charles River Laboratories Wins Five-Year, $95.7M Contract From National Institute Of Allergy And Infectious Diseases; Co. Will Manage And Provide Staffing For NIAID's Division Of Intramural Research Animal Care Program",2018-10-16 08:18:00-04:00,CRL,positive
297025.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,CRL,neutral
297026.0,"Baird Maintains Outperform on Charles River, Raises Price Target to $141",2018-09-17 08:32:00-04:00,CRL,neutral
297027.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,CRL,neutral
297028.0,"Morgan Stanley Maintains Equal-Weight on Charles River, Raises Price Target to $112",2018-09-11 07:27:00-04:00,CRL,neutral
297029.0,"Baird Healthcare Conference Concludes Today, Presenters Include: Charles River, Community Health, Cerus, GTx",2018-09-06 06:16:00-04:00,CRL,neutral
297030.0,"Argus Maintains Buy on Charles River, Raises Price Target to $140",2018-08-27 12:36:00-04:00,CRL,neutral
297031.0,"Pharma Supplier Charles River Laboratories Has Leading Competitive Position, Raymond James Says In Upgrade",2018-08-23 10:58:00-04:00,CRL,positive
297032.0,"Benzinga's Top Upgrades, Downgrades For August 23, 2018",2018-08-23 09:21:00-04:00,CRL,positive
297033.0,Raymond James Upgrades Charles River to Outperform,2018-08-23 07:25:00-04:00,CRL,neutral
297034.0,10 Biggest Price Target Changes For Tuesday,2018-08-21 09:41:00-04:00,CRL,neutral
297035.0,"Credit Suisse Maintains Neutral on Charles River, Lowers Price Target to $121",2018-08-21 07:06:00-04:00,CRL,positive
297036.0,"Analyst/Investor Meetings Today For Equifax and Charles River Labs, Respectively",2018-08-14 09:11:00-04:00,CRL,positive
297037.0,"The Week Ahead: Nvidia, Retailer Earnings In Focus",2018-08-13 13:26:00-04:00,CRL,neutral
297038.0,"Stocks Which Set New 52-Week High Yesterday, August 8th",2018-08-09 11:03:00-04:00,CRL,neutral
297039.0,"Jefferies Maintains Buy on Charles River, Raises Price Target to $145",2018-08-09 09:39:00-04:00,CRL,neutral
297040.0,"Charles Rivers Raises FY18 Sales Guidance From 18-20% To 19-21%, EPS $5.77-$5.92 To $5.85-$6.00",2018-08-08 07:02:00-04:00,CRL,neutral
297041.0,"Charles River Q2 EPS $1.62 Beats $1.46 Estimate, Sales $585.3M Beat $571.33M Estimate",2018-08-08 07:01:00-04:00,CRL,neutral
297042.0,"Earnings Scheduled For August 8, 2018",2018-08-08 06:03:00-04:00,CRL,neutral
297043.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,CRL,neutral
297044.0,"Stocks Which Set New 52-Week Highs Friday, August 3rd",2018-08-06 13:02:00-04:00,CRL,neutral
297045.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,CRL,neutral
297046.0,Stocks Which Set New 52-Week Highs Friday,2018-07-23 11:08:00-04:00,CRL,neutral
297047.0,Stocks Which Set New 52-Week High Yesterday,2018-07-20 09:05:00-04:00,CRL,neutral
297048.0,"Benzinga's Top Upgrades, Downgrades For July 17, 2018",2018-07-17 08:55:00-04:00,CRL,positive
297049.0,RBC Capital Upgrades Charles River to Outperform,2018-07-17 06:40:00-04:00,CRL,neutral
297050.0,"Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade",2018-06-15 09:23:00-04:00,CRL,neutral
297051.0,"Benzinga's Top Upgrades, Downgrades For June 15, 2018",2018-06-15 09:05:00-04:00,CRL,positive
297052.0,"The Market In 5 Minutes: Tariffs, NXPI, Powell And More",2018-06-15 08:59:00-04:00,CRL,neutral
297053.0,KeyBanc Upgrades Charles River to Overweight,2018-06-15 06:13:00-04:00,CRL,negative
297054.0,"Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: TherapeuticsMD, Charles River, OSI Systems, Odonate Therapeutics, Syros, Alnylam, Gilead, and Celgene",2018-06-06 07:29:00-04:00,CRL,neutral
297055.0,"Charles River Raises FY18 Adj. EPS Outlook From $5.67-$5.82 to $5.77-$5.92 vs $5.76 Est., Sales Growth Outlook From 16-18% to 18-20%",2018-05-10 09:01:00-04:00,CRL,positive
297056.0,"Charles River Q1 Adj. EPS $1.38 Beats $1.26 Estimate, Sales $493.97M Beat $480.56M Estimate",2018-05-10 08:59:00-04:00,CRL,neutral
297057.0,"Earnings Scheduled For May 10, 2018",2018-05-10 04:00:00-04:00,CRL,neutral
297058.0,"Benzinga's Top Upgrades, Downgrades For April 20, 2018",2018-04-20 09:16:00-04:00,CRL,positive
297059.0,"Mitsubishi UFJ Initiates Coverage On Charles River with Neutral Rating, Announces $115.00 Price Target",2018-04-20 08:31:00-04:00,CRL,neutral
297060.0,"Morgan Stanley Maintains Equal-Weight on Charles River, Raises Price Target to $102.00",2018-03-14 09:51:00-04:00,CRL,neutral
297061.0,5 Biggest Price Target Changes For Wednesday,2018-02-14 09:42:00-05:00,CRL,neutral
297062.0,"Benzinga's Top Upgrades, Downgrades For February 14, 2018",2018-02-14 09:32:00-05:00,CRL,positive
297063.0,"JP Morgan Maintains Overweight on Charles River, Raises price target to $120.00",2018-02-14 08:18:00-05:00,CRL,neutral
297064.0,SunTrust Robinson Humphrey Upgrades Charles River to Buy,2018-02-14 07:43:00-05:00,CRL,neutral
297065.0,Charles River Labs Acquires MPI Research for $800M Cash,2018-02-13 07:13:00-05:00,CRL,neutral
297066.0,UPDATE: Charles River Laboratories Sees FY18 Guidance Including MPI Of $5.67-$5.82 vs $5.58 Est.,2018-02-13 07:04:00-05:00,CRL,neutral
297067.0,Charles River Laboratories Sees FY18 Adj. EPS $5.42-$5.57 vs $5.58 Est.,2018-02-13 07:03:00-05:00,CRL,neutral
297068.0,"Charles River Laboratories Reports Q4 Adj. EPS $1.40 vs $1.25 Est., Sales $478.5M vs $474.5M Est.",2018-02-13 07:03:00-05:00,CRL,neutral
297069.0,"Charles River Laboratories Names Dr. Davide Molho President, COO",2018-02-13 07:03:00-05:00,CRL,neutral
297070.0,"Earnings Scheduled For February 13, 2018",2018-02-13 04:41:00-05:00,CRL,neutral
297071.0,"Charles River Labs Reports Investment In High-Throughput Screening Infrastructure, No Terms Disclosed",2018-02-01 08:03:00-05:00,CRL,negative
297072.0,Charles River Shares Down 2% Mon. Following SunTrust Downgrade From Buy To Hold,2018-01-22 09:53:00-05:00,CRL,positive
297073.0,"Evercore ISI Group Initiates Coverage On Charles River with In-Line Rating, Announces $117.00 Price Target",2018-01-19 08:21:00-05:00,CRL,neutral
297074.0,Charles River Laboratories Acquires KWS BioTest For ~$20M,2018-01-11 07:04:00-05:00,CRL,neutral
297075.0,"Benzinga's Top Upgrades, Downgrades For December 13, 2017",2017-12-13 09:01:00-05:00,CRL,positive
297076.0,"Argus Initiates Coverage On Charles River with Buy Rating, Announces $120.00 Price Target",2017-12-13 07:45:00-05:00,CRL,neutral
297077.0,Charles River Labs Reports Success Of Integrated Discovery Project With ENYO Pharma,2017-11-28 08:06:00-05:00,CRL,positive
297078.0,"Lightning Round: Jim Cramer Advises His Viewers On Mallinckrodt, GoPro And More",2017-11-16 07:26:00-05:00,CRL,neutral
297079.0,"Jefferies Maintains Buy on Charles River, Lowers Price Target to $124.00",2017-11-13 10:48:00-05:00,CRL,negative
297080.0,"Bank of America Maintains Buy on Charles River, Lowers Price Target to $115.00",2017-11-10 11:56:00-05:00,CRL,negative
297081.0,"Charles River Laboratories Increases FY17 Sales Growth From 8.5-10% to 9.75-10.5%, EPS $5.00-$5.15 To $5.08-$5.18",2017-11-09 07:11:00-05:00,CRL,positive
297082.0,"Charles River Laboratories Reports Q3 Adj. EPS $1.30 vs $1.22 Est., Sales $464.2M vs $458.7M Est.",2017-11-09 07:11:00-05:00,CRL,neutral
297083.0,"Earnings Scheduled For November 9, 2017",2017-11-09 04:08:00-05:00,CRL,neutral
297084.0,"Charles River Labs Reports Partnership With InSphero For In Vitro Drug Discovery, Development",2017-10-26 08:22:00-04:00,CRL,neutral
297085.0,"RBC Capital Initiates Coverage On Charles River with Sector Perform Rating, Announces $110.00 Price Target",2017-09-19 07:04:00-04:00,CRL,neutral
297086.0,"Charles River Labs Reaffirms FY 2017 Adj. EPS Guidance, Raises Sales Guidance",2017-08-09 07:31:00-04:00,CRL,neutral
297087.0,"Charles River labs Q2 Adj. EPS $1.29 vs $1.22 Est., Sales $469.1M vs $458.0M Est.",2017-08-09 07:30:00-04:00,CRL,neutral
297088.0,"Earnings Scheduled For August 9, 2017",2017-08-09 04:41:00-04:00,CRL,neutral
297089.0,Charles River Labs Acquires Brain On-Line for EUR 18M,2017-08-07 07:33:00-04:00,CRL,neutral
297090.0,"Jefferies Highlights A Pair Trade In Pharma: Buy ICON, Hold Tight On INC Research",2017-06-29 14:46:00-04:00,CRL,neutral
297093.0,4 Medical Stocks That Could Be Big Winners Next Week,2017-05-05 16:26:00-04:00,CRL,positive
297094.0,Charles River Labs Drops to Low of $86.44 on Volume,2017-04-07 10:47:00-04:00,CRL,negative
297095.0,"Nimbus Therapeutics, Charles River Labs Report Strategic Partnership to Advance New Therapeutic Programs",2017-04-05 08:05:00-04:00,CRL,neutral
297096.0,A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Yellen Speech,2017-02-14 07:59:00-05:00,CRL,negative
297097.0,Charles River Labs Sees FY 2017 EPS $5.00 to $5.10 vs $5.05 Est,2017-02-14 06:31:00-05:00,CRL,neutral
297098.0,"Charles River Labs Q4 EPS $1.21 vs $1.11 Est, Revenue $466.8M vs $441.6M Est",2017-02-14 06:31:00-05:00,CRL,neutral
297099.0,"Earnings Scheduled For February 14, 2017",2017-02-14 04:49:00-05:00,CRL,neutral
297100.0,"Benzinga's Top Upgrades, Downgrades For January 4, 2017",2017-01-04 09:41:00-05:00,CRL,positive
297101.0,Evercore ISI Group Upgrades Charles River to Buy,2017-01-04 08:21:00-05:00,CRL,neutral
297102.0,Goldman Sachs Upgrades Charles River to Neutral,2016-12-16 06:05:00-05:00,CRL,neutral
297103.0,Benzinga's Top Upgrades,2016-11-30 08:50:00-05:00,CRL,positive
297104.0,Barclays Upgrades Charles River to Equal-Weight,2016-11-30 08:28:00-05:00,CRL,neutral
297105.0,Charles River Labs Narrows FY16 Adj. EPS Outlook from $4.40-$4.50 to $4.44-$4.49 vs $4.46 Est.,2016-11-02 07:11:00-04:00,CRL,neutral
297106.0,"Charles River Labs Reports Q3 Adj. EPS $1.18 vs $1.13 Est., Sales $425.7M vs $434.4M Est.",2016-11-02 07:10:00-04:00,CRL,neutral
297107.0,Charles River Labs Reports Purchase of Agilux Labs for $64M in Cash,2016-09-28 16:32:00-04:00,CRL,neutral
297108.0,UBS Downgrades Charles River to Sell,2016-09-06 05:32:00-04:00,CRL,neutral
297109.0,Charles River Laboratories Partners with Milner Therapeutics Institute and Consortium,2016-08-08 17:04:00-04:00,CRL,neutral
297110.0,Charles River Laboratories Raises Fy16 EPS From $4.32-$4.45 To $4.40-$4.50,2016-08-03 07:10:00-04:00,CRL,neutral
297111.0,"Charles River Laboratories Reports Q2 EPS $1.20 vs. Est. $1.10, Rev. $434.1M vs. Est. $425M",2016-08-03 07:09:00-04:00,CRL,neutral
297112.0,"Charles River Laboratories announced that it has acquired Blue Stream Laboratories, no terms",2016-06-27 16:34:00-04:00,CRL,negative
297113.0,Positives In Charles River Labs 'Largely Reflected In Industry-High Valuation',2016-06-21 08:03:00-04:00,CRL,positive
297114.0,"Credit Suisse Initiates Coverage on Charles River at Neutral, Announces $84.00 PT",2016-06-21 04:19:00-04:00,CRL,positive
297115.0,"Charles River Laboratories Reports  Q1 EPS $0.98 vs. Est. $0.90, Rev. $354.9M vs. Est. $354.9M",2016-05-04 07:03:00-04:00,CRL,neutral
297116.0,Gabelli & Co Initiates Coverage on Charles River at Buy,2016-04-26 06:46:00-04:00,CRL,neutral
297117.0,"Charles River Labs Announces $10M Investment in BioMotiv, Strategic Partnership",2016-04-13 16:30:00-04:00,CRL,neutral
297118.0,Mid-Morning Market Update: Markets Open Higher; Time Warner Posts Mixed Q4 Results,2016-02-10 09:49:00-05:00,CRL,neutral
297119.0,Charles Rivers Labs Sees FY16 Sales Growth 20%-23.5%,2016-02-10 07:08:00-05:00,CRL,positive
297120.0,Charles Rivers Labs Sees FY16 Adj. EPS $4.07-$4.17 vs $4.16 Est.,2016-02-10 07:07:00-05:00,CRL,neutral
297121.0,"Charles River Labs Reports Q4 GAAP EPS $0.69, Adj. EPS $1 vs $0.94 Est., Sales $353.9M vs $349M Est.",2016-02-10 07:07:00-05:00,CRL,neutral
297122.0,"Earnings Scheduled For February 10, 2016",2016-02-10 04:09:00-05:00,CRL,neutral
297123.0,Wells Fargo Earlier Downgraded Charles River to Outperform,2016-01-07 09:38:00-05:00,CRL,positive
297124.0,Charles River Announces Acquisition of WIL Research for $585M,2016-01-07 06:31:00-05:00,CRL,neutral
297125.0,Charles River Labs Announces Purchase on Oncotest GmbH for ~$36M,2015-11-18 16:15:00-05:00,CRL,neutral
297126.0,"Charles River Labs Reports Q3 Adj. EPS $1.03 vs $0.94 Est., Sales $349.5M vs $340M Est.",2015-11-04 07:06:00-05:00,CRL,neutral
297127.0,Benzinga's Top Upgrades,2015-10-12 09:09:00-04:00,CRL,positive
297128.0,Wells Fargo Upgrades Charles River to Market Perform,2015-10-12 06:20:00-04:00,CRL,positive
297129.0,"Credit Suisse Assumes Charles River at Neutral, Announces $84.00 PT",2015-08-14 04:47:00-04:00,CRL,positive
297130.0,"Charles River Labs Reports Q2 Adj EPS $0.96 Vs Est $0.97, Sales $339.6M Vs Est $339.59M; Raises FY 2015 EPS To $3.60-$3.70 vs Est $3.64",2015-07-30 07:14:00-04:00,CRL,neutral
297131.0,"Charles River Laboratories, AstraZeneca Renew Strategic Partnership Agreement",2015-07-30 07:09:00-04:00,CRL,positive
297132.0,Benzinga's Top Downgrades,2015-07-10 09:07:00-04:00,CRL,positive
297133.0,Bank of America Upgrades Charles River to Buy,2015-07-10 08:14:00-04:00,CRL,neutral
297134.0,"Barclays Cuts Charles River Labs, Sees Lack Of Demand Proof Over Long-Term",2015-07-10 08:11:00-04:00,CRL,negative
297135.0,"Morgan Stanley Maintains Equal-weight on Charles River, Raises PT to $68.00",2015-07-10 04:07:00-04:00,CRL,neutral
297136.0,"Barclays Downgrades Charles River to Underweight, Maintains $60.00 PT",2015-07-10 04:00:00-04:00,CRL,neutral
297137.0,US Stock Futures Jump Ahead Of Jobless Claims Data,2015-07-09 07:41:00-04:00,CRL,neutral
297138.0,Charles River Laboratories to Acquire Celsis International Ltd.,2015-07-09 07:00:00-04:00,CRL,neutral
297139.0,Jefferies Boosts Targets Across Pharmaceutical Service Stocks,2015-05-27 11:59:00-04:00,CRL,positive
297140.0,Charles River Labs Offers Slideshow Presentation Ahead of Deutsche Bank Conference: Expecting Q2 Adj. EPS to be Similar or Slightly Below $0.97,2015-05-06 09:09:00-04:00,CRL,neutral
297141.0,Benzinga's Top Upgrades,2015-05-04 09:01:00-04:00,CRL,positive
297142.0,Edward Jones Upgrades Charles River to Buy,2015-05-04 06:21:00-04:00,CRL,neutral
297143.0,"Charles River Labs Reports Q1 Adj. EPS $0.79 vs $0.82 Est., Sales $320.4M vs $324M Est.; Expecting FY15 Sales Growth 6.5-8%",2015-04-29 16:32:00-04:00,CRL,positive
297144.0,"Charles River Labs Int'l Reports Q1 Adj EPS $0.79 Vs Est $0.82, Revs $320.4M Vs Est $323.97M",2015-04-29 16:32:00-04:00,CRL,neutral
297145.0,Jefferies Previews Booming Biotech Earnings,2015-04-27 09:02:00-04:00,CRL,neutral
297146.0,Wells Fargo Downgrades Charles River to Underperform,2015-04-07 06:12:00-04:00,CRL,positive
297147.0,"SunTrust Robinson Humphrey Downgrades Charles River to Neutral, Raises PT to $88.00",2015-03-26 06:21:00-04:00,CRL,neutral
297148.0,"Charles Rivers Announces CFO Thomas Ackerman Retirement, David Smith Will Takeover CFO role",2015-02-24 16:32:00-05:00,CRL,neutral
297149.0,"Charles Rivers Labs Reports Q4 Adj. EPS $0.81 vs $0.71 Est., Sales $329.5M; Sees FY Adj. EPS $3.55-$3.65",2015-02-10 16:32:00-05:00,CRL,neutral
297150.0,"Earnings Scheduled For February 10, 2015",2015-02-10 04:42:00-05:00,CRL,neutral
297151.0,William Blair Upgrades Charles River to Outperform,2015-01-23 06:08:00-05:00,CRL,neutral
297152.0,ICON Is Now A Strong Buy: Should It Be In Your Portfolio?,2014-12-17 08:14:00-05:00,CRL,positive
297153.0,"Credit Suisse Maintains Neutral on Charles River Laboratories International, Inc., Raises PT to $67.00",2014-11-04 17:46:00-05:00,CRL,positive
297154.0,Top 4 NYSE Stocks In The Medical Laboratories & Research Industry With The Highest ROE,2014-11-04 05:22:00-05:00,CRL,positive
297155.0,"Jefferies Maintains Buy on Charles River Laboratories International, Inc., Raises PT to $75.00",2014-10-30 08:12:00-04:00,CRL,neutral
297156.0,"Charles River Laboratories International, Inc. Reports Q3 EPS of $0.86 vs $0.80 Est; Revenue of $327.60M vs $327.09M Est",2014-10-29 16:22:00-04:00,CRL,neutral
297157.0,"SunTrust Robinson Humphrey Upgrades Charles River Laboratories International, Inc. to Buy, Raises PT to $70.00",2014-10-15 06:06:00-04:00,CRL,neutral
297158.0,"Charles Rivers Holding Investor Meeting: Expecting Q3 Sales Growth in Low-Double Digits Range, Adj. EPS Similar YoY",2014-08-12 08:23:00-04:00,CRL,positive
297159.0,"Charles River Laboratories International, Inc. Raises FY2014 EPS Guidance from $3.15-3.25 to $3.25-3.35 vs $3.21 Est",2014-08-06 16:41:00-04:00,CRL,neutral
297160.0,"Charles River Laboratories International, Inc. Reports Q2 EPS of $0.97 vs $0.82 Est",2014-08-06 16:40:00-04:00,CRL,neutral
297161.0,"SunTrust Robinson Humphrey Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces $55.00 PT",2014-06-24 07:48:00-04:00,CRL,neutral
297162.0,UPDATE: Morgan Stanley Reiterates On Charles River Laboratories Following CEO Conference Call,2014-05-20 09:37:00-04:00,CRL,neutral
297163.0,"From Charles River Earnings Conf. Call: Expecting Q2 Adj. EPS Similar to Q1 Level, Expecting Qtr. Stronger Demand, Bookings",2014-05-01 09:03:00-04:00,CRL,positive
297164.0,"Charles River Laboratories International, Inc. Raises FY2014 EPS Guidance from $3.00-3.10 to $3.15-3.25 vs $3.15 Est, Sees Sales Growth in 9-11% Range, vs Prior Guidance of 3-5% Growth",2014-04-30 16:41:00-04:00,CRL,positive
297165.0,"Charles River Laboratories International, Inc. Reports Q1 EPS of $0.82 vs $0.74 Est; Revenue of $299.40M vs $302.08M Est",2014-04-30 16:40:00-04:00,CRL,neutral
297166.0,", Galapagos Complete Sale of BioFocus and Argenta Service Division Operations to Charles River Laboratories",2014-04-01 05:39:00-04:00,CRL,neutral
297167.0,"KeyBanc Initiates Coverage on Charles River Laboratories International, Inc. at Hold",2014-03-19 16:41:00-04:00,CRL,neutral
297168.0,Charles River Laboratories CEO Foster: 'Moving Earlier in the Drug Development Process is Going to be Very Important to Us',2014-03-18 18:31:00-04:00,CRL,positive
297169.0,Charles River Laboratories CEO Foster: 'We've Become Critical to the Drug Development Process',2014-03-18 18:30:00-04:00,CRL,negative
297170.0, Charles River Laboratories CEO Foster: 'We've Seen Our Clients Outsource a Lot More Work; They're Focused on Reducing Costs and What Makes Sense for Them',2014-03-18 18:29:00-04:00,CRL,positive
297171.0,Jim Cramer Interviews CEO James C. Foster of Charles River Laboratories on Mad Money,2014-03-18 18:20:00-04:00,CRL,negative
297172.0,10 Healthcare Stocks With Strong Growth For 2014: Investment Idea Of The Day,2014-02-26 12:54:00-05:00,CRL,positive
297173.0,"Citigroup Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces $64.00 PT",2014-02-18 09:10:00-05:00,CRL,neutral
297174.0,Morgan Stanley Feels Confidence in Charles River Laboratories Following Solid 4Q13 EPS Report,2014-02-12 09:36:00-05:00,CRL,positive
297175.0,"Charles River Laboratories International, Inc. Sees FY2014 EPS $3.00-3.10 vs $3.10 Est",2014-02-11 16:31:00-05:00,CRL,neutral
297176.0,"Charles River Laboratories International, Inc. Reports Q4 EPS of $0.73 vs $0.68 Est; Revenue of $289.20M vs $289.56M Est",2014-02-11 16:30:00-05:00,CRL,neutral
297177.0,"Earnings Scheduled For February 11, 2014",2014-02-11 04:34:00-05:00,CRL,neutral
297178.0,"Bank of America Maintains Neutral on Charles River Laboratories International, Inc., Raises PO to $55.00",2013-12-12 06:36:00-05:00,CRL,negative
297179.0,"Raymond James Upgrades Charles River Laboratories International, Inc. to Market Perform",2013-12-11 07:43:00-05:00,CRL,neutral
297180.0,Charles River Labs Adds $150M in Shares to Buyback Plan,2013-12-03 16:31:00-05:00,CRL,positive
297181.0,"Deutsche Bank Initiates Coverage on Charles River Laboratories International, Inc. at Hold, Announces $55.00 PT",2013-11-20 16:30:00-05:00,CRL,neutral
297182.0,"Charles River Laboratories International, Inc. Reports Q3 EPS of $0.64 vs $0.70 Est; Revenue of $292.10M vs $290.28M Est",2013-10-29 16:30:00-04:00,CRL,neutral
297183.0,UPDATE: Cantor Fitzgerald Initiates Coverage on Charles River Laboratories on Good Market Position,2013-10-02 09:03:00-04:00,CRL,positive
297184.0,"Cantor Fitzgerald Initiates Coverage on Charles River Laboratories International, Inc. at Buy, Announces $52.00 PT",2013-10-01 16:08:00-04:00,CRL,neutral
297185.0,"Credit Suisse Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces $50.00 PT",2013-09-24 06:42:00-04:00,CRL,positive
297186.0,"UBS Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces $49.00 PT",2013-09-17 07:22:00-04:00,CRL,neutral
297187.0,Charles River Labs Adds $100M to Buyback Plan,2013-07-31 16:26:00-04:00,CRL,neutral
297188.0,"Charles River Laboratories International, Inc. Reports Q2 EPS of $0.73 vs $0.71 Est; Revenue of $292.90M vs $294.19M Est",2013-07-31 16:25:00-04:00,CRL,neutral
297189.0,UPDATE: Goldman Sachs Downgrades Charles River Laboratories on RMS Guidance Risk,2013-06-18 09:23:00-04:00,CRL,negative
297190.0,"Goldman Sachs Downgrades Charles River Laboratories International, Inc. to Sell, Lowers PT to $38.00",2013-06-18 06:29:00-04:00,CRL,negative
297191.0,UPDATE: Sterne Agee Resumes Charles River Laboratories at Buy on Multiple Positive Factors,2013-06-12 10:22:00-04:00,CRL,positive
297192.0,"Sterne Agee Initiates Coverage on Charles River Laboratories International, Inc. at Buy, Announces $56.00 PT",2013-06-11 16:16:00-04:00,CRL,neutral
297193.0,"Raymond James Downgrades Charles River Laboratories International, Inc. to Underperform",2013-05-31 08:11:00-04:00,CRL,neutral
297194.0,Charles River Labs Spikes Higher,2013-05-14 11:05:00-04:00,CRL,neutral
297195.0,"Charles River Laboratories International, Inc. Reports Q1 EPS of $0.69 vs $0.71 Est; Revenue of $291.20M vs $294.54M Est",2013-05-01 16:31:00-04:00,CRL,neutral
297196.0,"Earnings Scheduled For May 1, 2013",2013-05-01 04:58:00-04:00,CRL,neutral
297197.0,"Citigroup Downgrades Charles River Laboratories International, Inc. to Sell, Lowers PT to $37.00",2013-04-03 06:48:00-04:00,CRL,negative
297198.0,"Wells Fargo Downgrades Charles River Laboratories International, Inc. to Market Perform",2013-03-27 07:38:00-04:00,CRL,positive
297199.0,Benzinga's Top Initiations,2013-03-18 08:47:00-04:00,CRL,positive
297200.0,UPDATE: Bank of America Initiates Charles River Laboratories at Neutral on Valuation,2013-03-18 08:09:00-04:00,CRL,neutral
297201.0,"Bank of America Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces $48.00 PO",2013-03-18 06:16:00-04:00,CRL,negative
297202.0,"UPDATE: ISI Group Reiterates Neutral Rating, Raises PT on Charles River Laboratories on In-Line 4Q12",2013-02-20 14:15:00-05:00,CRL,neutral
297203.0,"ISI Group Maintains Neutral on Charles River Laboratories International, Inc., Raises PT to $43.00",2013-02-20 12:46:00-05:00,CRL,neutral
297204.0,UPDATE: Jefferies Upgraded Charles River Laboratories to Buy on Tailwinds,2013-02-19 07:53:00-05:00,CRL,neutral
297205.0,"Jefferies Upgrades Charles River Laboratories International, Inc. to Buy, Raises PT to $50.00",2013-02-19 06:15:00-05:00,CRL,neutral
297206.0,"Charles River Laboratories International, Inc. Reports Q4 EPS of $0.64 vs $0.60 Est; Revenue of $280.10M vs $280.81M Est",2013-02-13 16:30:00-05:00,CRL,neutral
297207.0,"Earnings Scheduled For February 13, 2013",2013-02-13 02:13:00-05:00,CRL,neutral
297208.0,"UPDATE: Sterne Agee Reiterates Buy Rating, Raises PT on Charles River Laboratories",2013-01-14 14:10:00-05:00,CRL,neutral
297209.0,"Sterne Agee Maintains Buy on Charles River Laboratories International, Inc., Raises PT to $51.00",2013-01-14 09:40:00-05:00,CRL,neutral
297210.0,CRL CEO Foster: 'Large Drug Companies are Using Small Biotech Companies as their Discovery Engines',2013-01-09 18:32:00-05:00,CRL,neutral
297211.0,"CRL CEO Foster: 'As Drugs Roll Off Patent, More Companies with Begin to Use Our Services'",2013-01-09 18:31:00-05:00,CRL,neutral
297212.0,CRL CEO Foster: 'There are Conversations with Several Large Drug Companies',2013-01-09 18:29:00-05:00,CRL,neutral
297213.0,Jim Cramer Interviews CEO James C. Foster of Charles River Laboratories on Mad Money,2013-01-09 18:28:00-05:00,CRL,negative
297214.0,Charles Rivers Labs Reaffirms 2013 Outlook: EPS $2.80-2.90,2013-01-08 09:46:00-05:00,CRL,neutral
297215.0,Charles River Labs Closes Purchase of Majority Ownership of Vital River,2013-01-07 17:00:00-05:00,CRL,positive
297216.0,UPDATE: JP Morgan Upgrades Charles River Laboratories to Overweight on Risk/Reward  ,2012-12-13 12:06:00-05:00,CRL,neutral
297217.0,Benzinga's Top Upgrades,2012-12-13 07:07:00-05:00,CRL,positive
297218.0,"JP Morgan Upgrades Charles River Laboratories International, Inc. to Overweight, Raises PT to $42.00",2012-12-13 06:10:00-05:00,CRL,neutral
297219.0,Mid-Afternoon Market Update: Bernanke Press Conference Leads to Drop in the Markets,2012-12-12 15:56:00-05:00,CRL,negative
297220.0,"Mid-Day Market Update: Fed to Continue Stimulus, Markets Rise",2012-12-12 14:26:00-05:00,CRL,neutral
297221.0,UPDATE: ISI Group Cuts PT to $39 on Charles River Laboratories Following Negative Guidance  ,2012-12-12 13:41:00-05:00,CRL,negative
297222.0,"UPDATE: Charles River Sees FY13 EPS Growing at Higher Rate Than Sales, Sees Cash Flow $165-175M",2012-12-12 08:45:00-05:00,CRL,positive
297223.0,"Charles Rivers Reaffirms FY12 Outlook; Sees FY13 EPS $2.80-2.90 vs $3.02, Sees Sales Growth 2.5-4.5%",2012-12-12 07:55:00-05:00,CRL,positive
297224.0,Top 4 NYSE Stocks In The Biotechnology Industry With The Highest ROA,2012-12-07 03:44:00-05:00,CRL,positive
297225.0,"UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Charles River Laboratories",2012-10-31 12:06:00-04:00,CRL,neutral
297226.0,"Jefferies & Company Maintains Charles River Laboratories International at Hold, Raises PT from $35 to $44",2012-10-31 08:03:00-04:00,CRL,neutral
297227.0,Charles River Labs Narrows FY EPS Guidance from $2.63-2.73 to $2.68-2.73 vs $2.73 Est,2012-10-30 16:54:00-04:00,CRL,neutral
297228.0,Charles River Laboratories International Reports Q3 EPS $0.65 vs $0.62 Est; Revenues $278.7M vs $278.86M Est,2012-10-30 16:34:00-04:00,CRL,neutral
297229.0,Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates,2012-10-24 03:27:00-04:00,CRL,positive
297230.0,Charles River Laboratories Enters Strategic Partnership with AstraZeneca,2012-10-17 08:04:00-04:00,CRL,neutral
297231.0,Charles River Opens New Biomedical Diagnostic Facility   ,2012-09-06 08:41:00-04:00,CRL,neutral
297232.0,Charles River Acquires Accugenix,2012-08-29 14:00:00-04:00,CRL,neutral
297233.0,"Charles River CEO Foster 'Increasingly, Lab Animal Models will Provide Better Translatable Info to Drug Industry'",2012-08-13 18:51:00-04:00,CRL,positive
297234.0,Charles River CEO Foster 'Our Goal is to Get Large Drug Companies to Outsource their Clinical Work to Us',2012-08-13 18:49:00-04:00,CRL,neutral
297235.0,Charles River CEO Foster 'We Help Companies with Elimination Process to Decide which Drugs to Keep',2012-08-13 18:47:00-04:00,CRL,positive
297236.0,Jim Cramer Interviews CEO James C. Foster of Charles River Laboratories  on Mad Money,2012-08-13 18:45:00-04:00,CRL,negative
297237.0,"PREVIEW: Jim Cramer to Interview CEO's of Regeneron, Charles River on Mad Money",2012-08-13 18:11:00-04:00,CRL,negative
297238.0,"Charles River Laboratories Guides FY $2.63-2.73, Had Seen $2.60-2.70 vs $2.69 Est",2012-08-07 16:36:00-04:00,CRL,neutral
297239.0,Charles River Laboratories International Reports Q2 EPS $0.75 vs $0.66 Est; Revenues $284.7M vs $286.16M Est,2012-08-07 16:33:00-04:00,CRL,neutral
297240.0,Charles River Labs Files Mixed Securities Shelf,2012-07-31 17:41:00-04:00,CRL,positive
297241.0,"UPDATE: ISI Group Initiates Charles River Labs With Underweight, $34 PT Demand, Preclinical Headwinds  ",2012-07-10 08:58:00-04:00,CRL,negative
297242.0,"ISI Group Initiates Coverage on Charles River Laboratories International at Underweight, Announces PT of $34",2012-07-10 06:07:00-04:00,CRL,neutral
297243.0,Charles River Laboratories International Reports Q1 EPS $0.7 vs $0.65 Est; Revenues $286M vs $286.58M Est,2012-05-02 16:34:00-04:00,CRL,neutral
297244.0,UPDATE: Sterne Agee Raises PT to $45 on Charles River Laboratories,2012-04-02 09:32:00-04:00,CRL,neutral
297245.0,"Sterne Agee Maintains Charles River Laboratories International at Buy, Raises PT from $43 to $45",2012-04-02 06:49:00-04:00,CRL,neutral
297246.0,UPDATE: Piper Jaffray Downgrades Arena Pharmaceuticals to Neutral,2012-03-28 06:36:00-04:00,CRL,neutral
297247.0,JP Morgan on MAP Pharmaceuticals Delayed Approval of Levadex,2012-03-27 07:49:00-04:00,CRL,positive
297248.0,Charles River Laboratories Guides FY 2012 EPS $2.60-2.70 vs $2.64 Est,2012-02-13 16:33:00-05:00,CRL,neutral
297249.0,Charles River Laboratories International Reports Q4 EPS $0.69 vs $0.56 Est; Revenues $291.00M vs $282.74M Est	,2012-02-13 16:30:00-05:00,CRL,neutral
297250.0,US Stock Futures Signal Higher Start On Wall Street,2012-02-13 06:22:00-05:00,CRL,neutral
297251.0,Stocks To Watch For February 13,2012-02-13 05:05:00-05:00,CRL,neutral
297252.0,Earnings Scheduled For February 13,2012-02-13 05:03:00-05:00,CRL,neutral
297253.0,"Holder & Obama's Propaganda is ""Belied by a Troublesome Little Thing Called Facts""",2012-01-30 06:32:00-05:00,CRL,negative
297254.0,"Benzinga's M&A Chatter for Tuesday January 10, 2012",2012-01-10 18:43:00-05:00,CRL,neutral
297255.0,JP Morgan Reiterates BioMimetic Therapeutics Neutral,2012-01-04 13:05:00-05:00,CRL,positive
297256.0,"UPDATE: Citigroup Maintains Neutral, Lowers PT to $31 on Charles River Laboratories ",2011-12-15 07:33:00-05:00,CRL,negative
297257.0,Citigroup Lowers PT on Charles River Laboratories to $31,2011-12-15 05:50:00-05:00,CRL,negative
297258.0,UPDATE: Deutsche Bank Lowers PT on Charles River Laboratories to $28,2011-12-14 11:25:00-05:00,CRL,negative
297259.0,Deutsche Bank Maintains Hold After Charles River Releases 2012 Guidance,2011-12-14 07:49:00-05:00,CRL,neutral
297260.0,Charles River Sees 2012 Non-GAAP EPS of $2.60-2.70 vs 2.67 Est,2011-12-14 07:01:00-05:00,CRL,neutral
297261.0,Notable Call Options Activity in Charles River Laboratories,2011-12-12 10:07:00-05:00,CRL,neutral
297262.0,"Sterne Agee Maintains Buy, PT of $43 on Charles River Laboratories ",2011-12-05 07:38:00-05:00,CRL,neutral
297263.0,UPDATE: Piper Jaffray Upgrades Arena Pharma to Overweight and Raises PT to $3 ,2011-11-28 07:39:00-05:00,CRL,negative
297264.0,UPDATE: Credit Suisse Lowering Price Target on Alimera Sciences,2011-11-15 08:14:00-05:00,CRL,positive
297265.0,"Sterne Agee Initiates Charles River Laboratories Coverage: Buy, $43 PT",2011-11-14 16:17:00-05:00,CRL,neutral
297266.0,pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIENÂ® for DME   ,2011-11-11 12:29:00-05:00,CRL,neutral
297267.0,Charles River Laboratories Sees 2011 EPS $2.40-$2.45 vs $2.45 Est (Saw $2.38-$2.48),2011-11-01 16:53:00-04:00,CRL,neutral
297268.0,Charles River Labs Reports Q3 EPS $0.57 vs $0.58 Est; Sales $277.6M vs $280.45M Est		,2011-11-01 16:52:00-04:00,CRL,neutral
297269.0,Scientific Consortium Awarded Knockout Mouse Project Grant from the National Institutes of Health,2011-09-29 10:01:00-04:00,CRL,positive
297270.0,McNicoll Lewis Vlak Raises PT on Transcept Pharmaceuticals to $8,2011-09-28 10:13:00-04:00,CRL,neutral
297271.0,Jefferies Has Hold On Charles River Laboratories ,2011-08-24 07:36:00-04:00,CRL,neutral
297272.0,Charles River Announces New Business Alignment; Doesn't Expect Segment Reporting Change,2011-08-23 16:32:00-04:00,CRL,neutral
297273.0,UPDATE: Jefferies Lowers PT on Charles River Laboratories to $33,2011-08-09 07:31:00-04:00,CRL,negative
297274.0,Jefferies Lowers PT On Charles River Laboratories To $33,2011-08-09 06:26:00-04:00,CRL,negative
297276.0,Charles River Reports Q2 Cont Ops EPS $0.66 vs $0.60 Est; Revenues $288.3M vs $287.90M Est 		,2011-08-02 16:31:00-04:00,CRL,neutral
297277.0,Jefferies Reports FDA Votes Against BMY Dapagliflozin Approval,2011-07-20 07:47:00-04:00,CRL,positive
297278.0,Who Wants to Buy Some Drugs?,2011-07-19 11:09:00-04:00,CRL,neutral
297279.0,Jefferies Raises PT On Charles River Laboratories To $44,2011-05-05 09:05:00-04:00,CRL,neutral
297280.0,"J.P. Morgan Reports ""Generally Soft"" 1Q Results For Charles River Laboratories",2011-05-04 09:07:00-04:00,CRL,neutral
297281.0,Goldman Sachs Reports Charles River Laboratories EPS Higher Than Expected (CRL),2011-05-04 08:51:00-04:00,CRL,neutral
297282.0,JP Morgan Raises PT On Charles River Laboratories To $38,2011-05-04 06:42:00-04:00,CRL,positive
297283.0,Charles River Labs Reports EPS of $0.61 vs. $0.55 Estimate; Revenues $285.8M vs. $279.17M Estimate,2011-05-03 16:30:00-04:00,CRL,neutral
297284.0,Charles River to Supply Pfizer's Genetically Modified Research Models   ,2011-03-03 08:35:00-05:00,CRL,neutral
297285.0,Charles River Implements $150M Accelerated Stock Repurchase Program ,2011-02-24 09:01:00-05:00,CRL,neutral
297286.0,Deutsche Bank Reiterates Hold On XenoPort (XNPT),2011-02-17 07:16:00-05:00,CRL,neutral
297287.0,Wells Fargo Raises CRL Valuation Range To $44-$45 from $42-$43,2011-02-10 10:00:00-05:00,CRL,positive
297288.0,Jefferies Lowers PT Of Charles River Laboratories To $35 (CRL),2011-02-10 09:06:00-05:00,CRL,negative
297289.0,Jefferies Raises PT On Charles River Laboratories To $40,2011-02-10 08:09:00-05:00,CRL,neutral
297290.0,CRL Revenue Exceeds Jefferies Estimate By $3.6M,2011-02-09 09:23:00-05:00,CRL,neutral
297291.0,Goldman Sachs Remains Neutral On Charles River Laboratories (CRL),2011-02-09 08:00:00-05:00,CRL,neutral
297292.0,Setback for Orexigen - Analyst Blog,2011-02-02 09:52:00-05:00,CRL,neutral
297293.0,Setback for Orexigen - Analyst Blog,2011-02-02 09:30:00-05:00,CRL,neutral
297294.0,Earnings Preview: Alkermes - Analyst Blog,2011-01-31 13:03:00-05:00,CRL,neutral
297295.0,Earnings Preview: Alkermes - Analyst Blog,2011-01-31 12:30:00-05:00,CRL,neutral
297296.0,Cost Control Helps Amylin Cut Loss - Analyst Blog,2011-01-27 10:31:00-05:00,CRL,negative
297297.0,Cost Control Helps Amylin Cut Loss - Analyst Blog,2011-01-27 10:15:00-05:00,CRL,negative
297298.0,Boost for VRX-GSK Epilepsy Drug - Analyst Blog,2011-01-25 10:01:00-05:00,CRL,positive
297299.0,Boost for VRX-GSK Epilepsy Drug - Analyst Blog,2011-01-25 09:45:00-05:00,CRL,positive
297300.0,"Jefferies Pharmaceuticals Update (CRL, PPDI, WX) ",2011-01-25 08:17:00-05:00,CRL,neutral
297301.0,Charles River Laboratories Adds Two New Board Members ,2011-01-24 16:19:00-05:00,CRL,neutral
297302.0,AstraZeneca Responds to FDA Letter - Analyst Blog,2011-01-24 16:01:00-05:00,CRL,neutral
297303.0,AstraZeneca Responds to FDA Letter - Analyst Blog,2011-01-24 15:40:00-05:00,CRL,neutral
297304.0,PPDI Guides Above Expectations  - Analyst Blog,2011-01-20 10:31:00-05:00,CRL,neutral
297305.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 10:01:00-05:00,CRL,negative
297306.0,PPDI Guides Above Expectations  - Analyst Blog,2011-01-20 10:00:00-05:00,CRL,neutral
297307.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 09:45:00-05:00,CRL,negative
297308.0,Good News for Cumberland Pharma - Analyst Blog,2011-01-14 11:31:00-05:00,CRL,positive
297309.0,Good News for Cumberland Pharma - Analyst Blog,2011-01-14 11:00:00-05:00,CRL,positive
297310.0,Endo Pharma Receives CRL - Analyst Blog,2011-01-10 12:31:00-05:00,CRL,neutral
297311.0,Endo Pharma Receives CRL - Analyst Blog,2011-01-10 12:02:00-05:00,CRL,neutral
297312.0,"Oppenheimer Maintains ENDP Rating, Estimates And PT",2011-01-10 07:48:00-05:00,CRL,neutral
297313.0,Valeant's 2011 Outlook Impresses - Analyst Blog,2011-01-07 11:06:00-05:00,CRL,positive
297314.0,Valeant's 2011 Outlook Impresses - Analyst Blog,2011-01-07 10:45:00-05:00,CRL,positive
297315.0,Recall of Liver Drug by CPIX - Analyst Blog,2011-01-04 10:39:00-05:00,CRL,neutral
297316.0,Recall of Liver Drug by CPIX - Analyst Blog,2011-01-04 10:00:00-05:00,CRL,neutral
297317.0,Theravance Evenly Poised  - Analyst Blog,2010-12-29 16:33:00-05:00,CRL,positive
297318.0,Theravance Evenly Poised  - Analyst Blog,2010-12-29 16:09:00-05:00,CRL,positive
297319.0,Cephalon Drops Jet Lag Indication  - Analyst Blog,2010-12-29 10:33:00-05:00,CRL,negative
297320.0,Verdict on MNKD's Afrezza Deferred - Analyst Blog,2010-12-29 10:03:00-05:00,CRL,positive
297321.0,Cephalon Drops Jet Lag Indication  - Analyst Blog,2010-12-29 10:00:00-05:00,CRL,negative
297322.0,Verdict on MNKD's Afrezza Deferred - Analyst Blog,2010-12-29 09:30:00-05:00,CRL,positive
297323.0,CRL for Alimera's Eye drug - Analyst Blog,2010-12-28 11:00:00-05:00,CRL,neutral
297324.0,CRL for Alimera's Eye drug - Analyst Blog,2010-12-28 09:45:00-05:00,CRL,neutral
297325.0,Alimera Sciences: Iluvien Approval Delayed By FDA,2010-12-28 07:34:00-05:00,CRL,positive
297326.0,FDA Rejection Sends pSivida Shares Down 20.1% (PSDV),2010-12-27 14:36:00-05:00,CRL,negative
297327.0,Afternoon Market Update,2010-12-27 12:05:00-05:00,CRL,neutral
297328.0,Setback for Cumberland Pharma - Analyst Blog,2010-12-27 10:00:00-05:00,CRL,neutral
297329.0,Vivus Seeks EU Nod for Qnexa - Analyst Blog,2010-12-27 09:30:00-05:00,CRL,neutral
297330.0,Setback for Cumberland Pharma - Analyst Blog,2010-12-27 09:30:00-05:00,CRL,neutral
297331.0,Vivus Seeks EU Nod for Qnexa - Analyst Blog,2010-12-27 08:45:00-05:00,CRL,neutral
297332.0,"Benzinga's Top Pre-Market NASDAQ Losers (PSDV, TSLA, MGIC, NFLX)",2010-12-27 08:43:00-05:00,CRL,negative
297333.0,A Peek Into The Market Before The Trading Starts,2010-12-27 08:06:00-05:00,CRL,neutral
297334.0,Oppenheimer Has Outperform Rating On Alimera Sciences (ALIM),2010-12-27 07:16:00-05:00,CRL,neutral
297335.0,Certriad Development Discontinued - Analyst Blog,2010-12-23 10:06:00-05:00,CRL,neutral
297336.0,Certriad Development Discontinued - Analyst Blog,2010-12-23 09:30:00-05:00,CRL,neutral
297337.0,Hapoaliom Views Arena's Lorcaserin As Unapprovable,2010-12-23 09:12:00-05:00,CRL,neutral
297338.0,Label Expansion Sought for Byetta - Analyst Blog,2010-12-23 09:03:00-05:00,CRL,neutral
297339.0,Label Expansion Sought for Byetta - Analyst Blog,2010-12-23 08:15:00-05:00,CRL,neutral
297340.0,Cumberland Pharmaceuticals Falls 10.9% On FDA News (CPIX),2010-12-22 16:24:00-05:00,CRL,neutral
297341.0,Another Setback for AstraZeneca  - Analyst Blog,2010-12-22 09:03:00-05:00,CRL,neutral
297342.0,Another Setback for AstraZeneca  - Analyst Blog,2010-12-22 08:15:00-05:00,CRL,neutral
297343.0,Arena Pharmaceuticals Set To Reopen 8:15am After FDA End-Of-Review (ARNA),2010-12-22 08:13:00-05:00,CRL,neutral
297344.0,Cumberland Pharmaceuticals FDA Rejection In CRL (CPIX),2010-12-22 07:32:00-05:00,CRL,negative
297345.0,King Pharma Files NDA for Pain Drug - Analyst Blog,2010-12-21 09:03:00-05:00,CRL,negative
297346.0,King Pharma Files NDA for Pain Drug - Analyst Blog,2010-12-21 08:30:00-05:00,CRL,negative
297347.0,Regulatory Setback for AstraZeneca - Analyst Blog,2010-12-17 19:03:00-05:00,CRL,neutral
297348.0,Regulatory Setback for AstraZeneca - Analyst Blog,2010-12-17 18:21:00-05:00,CRL,neutral
297349.0,Charles River's Business Outlook - Analyst Blog,2010-12-17 18:03:00-05:00,CRL,neutral
297350.0,Charles River's Business Outlook - Analyst Blog,2010-12-17 17:13:00-05:00,CRL,neutral
297351.0,J.P. Morgan Reports Disappointing Guidance for Charles River Laboratories,2010-12-14 10:35:00-05:00,CRL,negative
297352.0,Charles River Discusses Business Outlook (CRL),2010-12-14 07:57:00-05:00,CRL,neutral
297353.0,"VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting (VVUS)",2010-12-14 07:53:00-05:00,CRL,neutral
297354.0,Neutral on MannKind  - Analyst Blog,2010-12-10 16:03:00-05:00,CRL,neutral
297355.0,Neutral on MannKind  - Analyst Blog,2010-12-10 15:45:00-05:00,CRL,neutral
297356.0,Charles River Laboratories to Report Guidance,2010-12-10 08:57:00-05:00,CRL,neutral
297357.0,Cramer's 'Mad Money' Recap: Santa Bull's 12 Gifts (Update 1),2010-12-09 18:43:00-05:00,CRL,negative
297358.0,Goldman Sachs Maintains CRL Rating And PT Ahead Of Guidance Call,2010-12-09 09:45:00-05:00,CRL,neutral
297359.0,Setback for Valeant Epilepsy Drug - Analyst Blog,2010-12-03 18:00:00-05:00,CRL,neutral
297360.0,Setback for Valeant Epilepsy Drug - Analyst Blog,2010-12-03 18:00:00-05:00,CRL,neutral
297361.0,Setback for Valeant Epilepsy Drug - Analyst Blog,2010-12-03 17:28:00-05:00,CRL,neutral
297362.0,Setback for Valeant Epilepsy Drug - Analyst Blog,2010-12-03 17:28:00-05:00,CRL,neutral
297363.0,An Update on Alexza Pharma (ALXA) - Analyst Blog,2010-12-03 12:06:00-05:00,CRL,neutral
297364.0,An Update on Alexza Pharma (ALXA) - Analyst Blog,2010-12-03 11:46:00-05:00,CRL,neutral
297365.0,Good News for Spectrum Pharma - Analyst Blog,2010-11-30 18:30:00-05:00,CRL,positive
297366.0,Good News for Spectrum Pharma - Analyst Blog,2010-11-30 12:41:00-05:00,CRL,positive
297367.0,Amylin Stays Neutral - Analyst Blog,2010-11-24 12:12:00-05:00,CRL,neutral
297368.0,Amylin Stays Neutral - Analyst Blog,2010-11-24 06:20:00-05:00,CRL,neutral
297369.0,"Charles River Misses, Trims Outlook - Analyst Blog",2010-11-12 14:33:00-05:00,CRL,negative
297370.0,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk       - Press Releases",2010-11-12 10:33:00-05:00,CRL,positive
297371.0,Wider Loss at Amylin - Analyst Blog,2010-11-11 12:33:00-05:00,CRL,negative
297372.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews,2010-11-09 17:03:00-05:00,CRL,neutral
297373.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook,2010-11-09 17:03:00-05:00,CRL,neutral
297374.0,Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook,2010-11-09 17:03:00-05:00,CRL,neutral
297375.0,Narrower Q3 Loss at CTIC - Analyst Blog,2010-11-05 12:32:00-04:00,CRL,negative
297376.0,J.P. Morgan Has A Note On Charles River Laboratories After Earnings (CRL),2010-11-04 06:59:00-04:00,CRL,neutral
297377.0,Loss at MNKD Wider than Expected - Analyst Blog,2010-11-02 11:00:00-04:00,CRL,negative
297378.0,Jefferies Remains Cautious On Vivus Pending Qnexa Approval,2010-11-01 08:30:00-04:00,CRL,positive
297379.0,J.P. Morgan Upgrades Vivus (VVUS),2010-10-29 07:31:00-04:00,CRL,neutral
297380.0,Rude Shock for Arena Pharma - Analyst Blog,2010-10-25 14:33:00-04:00,CRL,negative
297381.0,FDA Issues Complete Response For Arena's Lorcaserin,2010-10-25 10:08:00-04:00,CRL,neutral
297382.0,Rude Shock for Amylin - Analyst Blog,2010-10-20 19:09:00-04:00,CRL,negative
297383.0,Collins Stewart Lowers Amylin Price Target,2010-10-20 11:13:00-04:00,CRL,negative
297384.0," Charles River Announces Exclusive License with Transposagen Biopharmaceuticals, Inc.",2010-10-13 16:20:00-04:00,CRL,positive
297385.0,Cell Therapeutics Cut to Underperform - Analyst Blog,2010-10-07 23:36:00-04:00,CRL,negative
297386.0,CTIC Stays Neutral - Analyst Blog,2010-09-20 16:00:00-04:00,CRL,neutral
297387.0,Forest Labs Responds to CRL - Analyst Blog,2010-09-14 17:06:00-04:00,CRL,neutral
297388.0,CTIC to Challenge FDA Decision - Analyst Blog,2010-09-14 16:33:00-04:00,CRL,positive
297389.0,MannKind Evenly Poised - Analyst Blog,2010-09-10 17:06:00-04:00,CRL,positive
297390.0,Red Signal for AstraZeneca Drug - Analyst Blog,2010-09-07 11:42:00-04:00,CRL,neutral
297391.0,Jefferies Sees Limited Upside In Charles River Laboratories (CRL),2010-08-30 07:01:00-04:00,CRL,negative
297392.0,"CRL Misses, Curbs Expectations - Analyst Blog",2010-08-05 17:32:00-04:00,CRL,negative
297393.0,MannKind Q2 Loss Shrinks - Analyst Blog,2010-08-03 14:45:00-04:00,CRL,negative
297394.0,Price Target For Charles River Laboratories Revised Downwards (CRL) ,2010-08-03 13:22:00-04:00,CRL,neutral
297395.0,Charles River Falls 4% After Missing Estimates (CRL),2010-08-02 14:59:00-04:00,CRL,negative
297396.0,Charles River Misses Estimates (CRL),2010-08-02 07:14:00-04:00,CRL,negative
297397.0,"Piper Jaffray report on WuXi Pharma Tech, Inc",2010-07-30 12:20:00-04:00,CRL,neutral
297398.0,Charles River Scraps WuXi Takeover Bid,2010-07-30 05:40:00-04:00,CRL,neutral
297399.0,JANA Partners Urges All Charles River Shareholders to Vote Against Proposed WuXi Acquisition ,2010-07-29 16:04:00-04:00,CRL,neutral
297400.0,Good News for MannKind - Analyst Blog,2010-07-23 18:06:00-04:00,CRL,positive
297401.0,Good News for MannKind - Analyst Blog,2010-07-21 14:42:00-04:00,CRL,positive
297402.0,Pharma and Biotech Industry Outlook - July 2010 - Zacks Analyst Interviews,2010-07-21 08:20:00-04:00,CRL,neutral
297403.0,Pharma and Biotech Industry Outlook - July 2010 - Industry Outlook,2010-07-21 08:20:00-04:00,CRL,neutral
297404.0,Pharma and Biotech Industry Outlook - July 2010 - Industry Outlook,2010-07-20 17:45:00-04:00,CRL,neutral
297405.0," JANA Partners Addresses Charles River's Latest Defense of Proposed WuXi Acquisition (CRL, WX)",2010-07-16 09:46:00-04:00,CRL,positive
297406.0,Charles River Schedules The Release Of Second-Quarter Results,2010-07-15 09:34:00-04:00,CRL,neutral
297407.0,Encouraging Data on MNKD's Afrezza - Analyst Blog,2010-06-30 10:37:00-04:00,CRL,positive
297408.0,MannKind Presents Positive Data - Analyst Blog,2010-06-11 14:45:00-04:00,CRL,positive
297409.0,Jefferies Reiterates Hold Rating on Charles River (CRL),2010-06-02 09:55:00-04:00,CRL,neutral
297410.0,Update on Xenoport's Horizant - Analyst Blog,2010-05-27 13:06:00-04:00,CRL,neutral
297411.0,Target Date for Cadence Drug - Analyst Blog,2010-05-18 18:08:00-04:00,CRL,neutral
297412.0,Bullish Bet on Charles River Labs,2010-05-05 12:21:00-04:00,CRL,neutral
297413.0,MannKind Loss Shrinks - Analyst Blog,2010-05-03 14:06:00-04:00,CRL,negative
297414.0,"Afternoon Market Update Charles River Laboratories (NYSE: CRL), WuXi PharmaTech (WX), Duke Energy (NYSE: DUK), PPL (NYSE: PPL), CKE Restaurants (NYSE: CKR)",2010-04-26 16:23:00-04:00,CRL,positive
297415.0,Charles River (CRL) To Enter China With An Acquisition,2010-04-26 10:14:00-04:00,CRL,neutral
297416.0,"Company News for April 26, 2010 - Corporate Summary",2010-04-26 09:30:00-04:00,CRL,neutral
297417.0,Charles River To Buy WuXi For $1.6 Billion,2010-04-26 05:36:00-04:00,CRL,neutral
297418.0,Theravance's Loss Widens - Analyst Blog,2010-04-22 10:30:00-04:00,CRL,negative
297419.0,Cell Therapeutics Cuts Jobs - Analyst Blog,2010-04-16 12:30:00-04:00,CRL,negative
297420.0,Cell's Pixantrone Denied Approval  - Analyst Blog,2010-04-09 13:30:00-04:00,CRL,positive
297421.0,21 Long Trade Setups with Stop-Losses,2010-04-01 21:04:00-04:00,CRL,neutral
297422.0,FDA Accepts Savient Drug BLA - Analyst Blog,2010-03-31 17:16:00-04:00,CRL,positive
297423.0,Setback for MannKind - Analyst Blog,2010-03-16 14:17:00-04:00,CRL,neutral
297424.0,Bayer Downgraded to Underperform - Analyst Blog,2010-03-15 11:15:00-04:00,CRL,neutral
297425.0,J&J Returns Drug Rights - Analyst Blog,2010-02-22 15:39:00-05:00,CRL,neutral
297426.0,Pipeline Setback for Glaxo - Analyst Blog,2010-02-19 12:33:00-05:00,CRL,neutral
297427.0,Theravance Misses Estimates - Analyst Blog,2010-02-12 15:55:00-05:00,CRL,negative
297428.0,Charles River Laboratoriesâ (CRL) Estimates Lowered,2010-02-11 10:20:00-05:00,CRL,negative
297429.0,"Trade Ideas for February 9, 2010",2010-02-09 06:52:00-05:00,CRL,neutral
297430.0,Wednesday's Hot Stocks: Finding A Rose Among Many Thorns,2010-01-14 08:42:00-05:00,CRL,neutral
297431.0,Tuesday's Breakout Stocks: Pumping up Your Portfolio with NBTY,2010-01-13 08:12:00-05:00,CRL,neutral
297432.0,Charles River Laboratories (CRL) To Suspend Operations Of Preclinical Services,2010-01-12 12:33:00-05:00,CRL,negative
297433.0,"Zacks Analyst Blog Highlights: Johnson & Johnson, ViroPharma, Theravance, Cubist Pharmaceutical and Pfizer - Press Releases",2010-01-04 07:46:00-05:00,CRL,neutral
297434.0,Pipeline Setback for JNJ - Analyst Blog,2009-12-31 10:43:00-05:00,CRL,neutral
297435.0,Setback for Endo Pharma - Analyst Blog,2009-12-11 10:46:00-05:00,CRL,neutral
297436.0,AstraZeneca: More Good News - Analyst Blog,2009-12-07 18:00:00-05:00,CRL,positive
297437.0,Setback for Theravance - Analyst Blog,2009-11-30 13:38:00-05:00,CRL,neutral
297438.0,Biogen's Rituxan Label Expansion Delayed - Analyst Blog,2009-11-20 11:00:00-05:00,CRL,negative
297439.0,GENZ's Lumizyme Approval Delayed - Analyst Blog,2009-11-17 15:56:00-05:00,CRL,positive
297440.0,"TheFortuneFinancial.com Free Market Research on BSX, ARW, CVG, WY, TS and CRL",2009-08-07 06:47:00-04:00,CRL,positive
